Business Wire

TN-ARIES-CLEAN-TECH

19.11.2021 17:49:06 CET | Business Wire | Press release

Share
Aries Linden Biosolids Gasification Plant Achieves Mechanical Completion

Aries has reached another major milestone, achieving mechanical completion of the Aries Linden Biosolids Gasification Plant in Linden, New Jersey. This fluidized bed gasification plant is currently the largest facility of its type in the world. Commissioning is underway and is expected to be completed over the next few months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211119005608/en/

At full capacity, the plant will process 430 tons of biosolids daily (130,000 tons per year) diverting it from local landfills. This will also result in the production of approximately 22 tons per day of beneficial Bio-Fly-Ash™, a renewable product that will be sold as an additive to local concrete companies. The plant is located in a re-purposed building within the Linden Roselle Sewerage Authority (LRSA) complex.

“A special congratulations to Renus Kelfkens, Aries Executive Vice President - Engineering and all the Aries Clean Technologies team on this major milestone,” said Gregory Bafalis , CEO of Aries. “These teams have worked thousands of hours and delivered all fabrication and installation within two years from groundbreaking. I have no doubt this technology will become a new standard for the safe conversion of biosolids into beneficial use products.

“Currently 90% of the domestic Class A biosolids market is disposed of through ineffective conventional means such as landfilling, land application, or incineration. The fluidized bed technology can safely and efficiently stop this now and generate clean energy and Bio-Fly-Ash™,” Bafalis added.

“We’ve looked forward to celebrating this historic date that brings new technology and progress towards a cleaner environment to Linden and the Garden State,” said Derek Armstead , Mayor of Linden. “The Aries Build-Own-Operate model provides no financial risk to the LRSA or to the City of Linden but brings with it new, high-paying, green jobs in the clean tech industry for the people of Linden. And I’m so pleased that 16 new, permanent positions will bring this plant to life. We look forward to a long partnership with the Aries Linden team.”

Even before construction began, collaborations were underway with LRSA and the State of New Jersey Department of Environmental Protection (NJDEP). The awarding of the environmental permits not only validates Aries biosolids solutions but helps bring the state closer to its environmental goals. Permits addressed areas such as site use, soil conservation, air quality, water usage, and electrical generation and consumption.

Financing was provided in part through the sale of $61.5 million of “Green” tax-exempt bonds issued through the Union County Improvement Authority. Equity for the project comes principally from Aries Clean Technologies and Spring Lane Capital . “This project and Aries’ gasification technology fit perfectly with Spring Lane’s investment approach of partnering with leaders in the energy, water, food, and waste industries to help them deploy innovative, sustainable solutions. We are thrilled to support the Aries team on this and future projects,” said Nikhil Garg, General Partner at Spring Lane Capital.

Current research indicates that the fluidized bed gasification process will become an efficient method to address and destroy the quickly growing problem of per- and polyfluoroalkyl substances (PFAS). These man-made chemicals are used in many industrial applications and are very pervasive in the environment and human body. PFAS accumulates over time, leading to adverse health effects. Current studies show that the high temperature reached during the gasification process destroys any PFAS in biosolids as well as other bacteria, viruses, mold, fungus, etc.

The closed-loop system runs primarily on clean sustainable, renewable synthetic gas rather than relying on fossil fuels during operations. It is carbon negative and captures methane (with a global warming impact 23 times greater than CO2) that would otherwise be released into the atmosphere through the decomposition of biosolids. Greenhouse gases will also be reduced due to the reduction in trucking miles to reach existing, conventional disposal methods.

LRSA, created in 1948, services the City of Linden and the Borough of Roselle. It was established to contract and operate wastewater treatment and interceptor facilities to collect, treat, and dispose of sewage generated by the municipalities.

In addition to being the lowest cost option for biosolids disposal in the Linden area, the plant will serve the largest metropolitan area in the U.S., New York, that includes New York City, Long Island, and the Mid and Lower Hudson Valley in the state of New York and five of the largest cities in New Jersey: Newark, Jersey City, Paterson, Elizabeth, and Edison, and their vicinities.

About Aries Clean Technologies

Aries Clean Technologies, based in Franklin, Tennessee, develops, designs, and builds innovative proprietary fluidized bed and downdraft gasification systems and projects using its eight patents granted to date. Its projects provide for the sustainable conversion of biosolids and biomass, reduction of carbon emissions, and the production of clean thermal and electrical energy and beneficial Aries GREEN ® Biochar or Bio-Fly-Ash™. For more information, please visit our website: www.ariescleantech.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye